



Groundbreaking R&D
meets world-class
product development
and commercialization



INVESTMENT HIGHLIGHTS

- Proprietary R&D conducted by a *world-class team* of medicinal chemists and pharmaceutical industry professionals
- Led by *CPG market veterans* with a proven track record of launching and scaling consumer product distribution programs while increasing company valuation by as much as 35-fold
- unbuzzd™, a rapid alcohol detoxification beverage, the first-to-market with a scientifically formulated powder stick and RTD beverage for this fast-growing consumer product category, *expected to grow 300% by 2030*
- rekvry™ a formulation for alcohol misuse treatment for use in emergency and hospital settings, an unmet need and has potential for *exponential growth*
- LUCID MS - *Potential multi-billion asset* in demyelinating diseases, with initial indication in multiple sclerosis (MS)

	Discovery	Lead	In vivo PoC	IND* enabling studies	P1	P2	P3	Market Launch
UNBUZZD™ (Recreational alcohol misuse treatment)								Q3 2024
REKVRY™ (Hospital and emergency settings alcohol misuse treatment)								
LUCID-21-302 (Multiple Sclerosis)					ongoing Q1 -Q3, 2023			

AN R&D FOCUSED BUSINESS MODEL

Tremendous revenue potential without the marketing cost burden

QUANTUM MAINTAINS:

7%

royalty on gross
revenue of unbuzzd™

25%

equity stake in Celly
Nu, a privately held
Canadian company
formed in 2023,
focused exclusively on
consumer
applications of alcohol
misuse treatment

100%

rights for all medical
and pharmaceutical
applications of this
alcohol misuse
treatment

100%

exclusive worldwide
patent rights to New
Chemical Entity (NCE)
for treatment of
multiple sclerosis and
other demyelinating
diseases

DEEP COMMERCIAL EXPERTISE



Gerry David, Director Co-Chair

- Former CEO of Celsius Holdings, a zero-calorie fitness drink maker, 35-fold increase in market cap, surpassing \$9 billion and enhancing shareholder value
- One of 25 Gold Winners in the esteemed CEO World Awards



John Duffy, CEO unbuzzd™

- Over 22 years in the Coca-Cola system including role of Vice President of National Sales, leading the customer management team responsible for Coca-Cola systems' largest foodservice distributor, Sysco



Kevin Harrington, Marketing

- Original Shark on Shark Tank
- Launched over 1,000 products in over 100 countries, creating over \$6 billion in global sales
- Instrumental in Celsius' influencer marketing program



Zeeshan Saeed, CEO and Founder of Quantum Director and Co-Chair of unbuzzd™

- President of ZZ Telecommunications, a long-distance communications carrier
- Extensive experience in international capital markets, having successfully assisted multiple start-ups in raising initial funding and securing listings on various stock exchanges

AWARD-WINNING EXPERTS ACROSS R&D AND HEALTHCARE

Dr. Laksmi P. Kotra, B.Pharm.(Hons), PhD, Director

- Professor of medicinal chemistry at Leslie Dan Faculty of Pharmacy, University of Toronto.
 - Senior Scientist at Krembil Research Institute, University Health Network, Toronto
 - Recipient of Julia Levy award, recognizing successful commercialization of Innovation in Canada
 - Led a number of important drug discovery and development projects, including anti- HIV drugs, antibacterials, insulin, antimalarials, medical cannabis-based therapeutics, and drugs targeting MS
-

Dr. Andrzej Chruscinski, MD, PhD

- Board-certified cardiologist, Led two major clinical trials investigating tolerance in transplantation and new biomarkers discovery
-

Dr. Eric Hoskins, Director

- Former Canada's Minister of Health in charge of North America's largest health system
-

Ashwini Joshi, MS, PG DIPLOMA (QA & RA)

- Deep expertise in developing formulations of small molecules for global markets in mid to large generic and pharmaceutical industries. Expert in product development at R&D to its successful scale-up, subsequent regulatory filings and clinical development.

unbuzzd™ + rekvry™

Revolutionary alcohol misuse technology, life-changing opportunity



*Technology is currently patent-pending

EXCESSIVE ALCOHOL USE CONTINUES TO WREAK HAVOC ON FAMILIES AND COMMUNITIES, CREATING A HEAVY STRAIN ON SOCIETY AS A WHOLE



Binge drinking rates among adults aged 35–50 reached an **all-time high** in 2023¹



Rates of binge drinking among people ages 18 to 25 have been decreasing in the past decade, but **remain high** (28.7% in 2023)²




Excessive drinking cost the United States about **\$249 billion annually** when combining healthcare costs, lost productivity and earnings, criminal justice implications, vehicle crashes, and property damages³

Whether you drink or not, everybody pays the price

1. <https://www.nih.gov/news-events/news-releases/marijuana-hallucinogen-use-binge-drinking-reached-historic-highs-among-adults-35-50>
2. [https://www.niaaa.nih.gov/publications/brochures-and-fact-sheets/binge-drinking#:~:text=Young%20Adults%3A%20Rates%20of%20binge,\(28.7%25%20in%202023\).&text=According%20to%20the%202022%20NSDUH,drinking%20in%20the%20past%20month.](https://www.niaaa.nih.gov/publications/brochures-and-fact-sheets/binge-drinking#:~:text=Young%20Adults%3A%20Rates%20of%20binge,(28.7%25%20in%202023).&text=According%20to%20the%202022%20NSDUH,drinking%20in%20the%20past%20month.)
3. <https://www.cdc.gov/drinklessbeyourbest/excessivedrinking.html>

AS EXCESSIVE ALCOHOL USE PERSISTS, THE HANGOVER REMEDY MARKET CONTINUES TO GROW

Global Market Forecast (USD Million)




Source: GRAND VIEW RESEARCH

- The global hangover cure products market size was valued at USD 2.05 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 14.8% from 2023 to 2030 when it is expected to reach a value of USD 6.2 billion.
- But until now, there is no effective product that **reverses** the effects of alcohol efficiently.

THE DAYS OF “WAITING IT OUT” ARE OVER

unbuzzd™ is the only dietary supplement product that provides relief from inebriation and accelerates alcohol metabolism, leading to reduced Breath Alcohol Concentration (BrAC)

HOW IT WORKS:



unbuzzd™: Contains ingredients that accelerate the Metabolism, Restoring Mental Alertness, & Supporting Faster Recovery from Alcohol Inebriation

Source: Quantum Biopharma Pharma Inc.


*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

unbuzzd™ BENEFITS



Rapid Restoration

Restores mental alertness and improves cognition post-alcohol consumption in an average of 15-30 minutes



Improved Liver and Brain Function

Proprietary formulation of extracts, vitamins, minerals help with liver and brain function



Reduced Blood Alcohol Content

Ingredients help reduce BAC faster than what the body would do naturally

MULTI-CHANNEL DISTRIBUTION STRATEGY

Building on valuable customer data and subscription opportunities to meet consumers where they're at



Direct to Consumer: Launched August 2024 in the USA



Liquor, Foodservice, Travel: 2024 – 2026




Direct Store Delivery: 2024 – 2026



National Retail: 2025 – 2027

360 DEGREE MARKETING APPROACH



ALCOHOL MISUSE TREATMENT UPCOMING MILESTONES



unbuzzd™

- Raise awareness with open sponsorship influencer platform
- RTD formulation expected to be available Q1, 2025

rekvry™

rekvry™

- Dietary supplement trial studying the safety and efficacy of UNBUZZD™ in Acute Alcohol Intoxication is currently underway

LUCID-21-203:

A New Chemical Entity (NCE)
with the potential to reverse
multiple sclerosis and other
chronic neurological disorders




MULTIPLE SCLEROSIS (MS): A DEBILITATING DISEASE WITH HIGH UNMET NEED

- MS is characterized by **demyelination**: one of a group of disorders characterized by the destruction of myelin, the protective sheath that surrounds nerve fibers in the central nervous system
- **Myelin is essential** for proper functioning of nerves, helping to speed up the transmission of electrical signals between the brain and other parts of the body
- Patients who have MS suffer from a range of devastating symptoms, including vision loss, pain, fatigue, impaired coordination
- Current therapies for MS help reduce relapses and prevent worsening disability in some patients, but **they are not as effective** at slowing down disease progression or reversing damage over time¹

Patients suffering from MS need better options, fast.

AN EXPANSIVE MARKET

Prevalence of Multiple Sclerosis* 1 in 3,000 people around the globe



- Almost **1 million people** in the US alone have been diagnosed with MS and 2.8 million people worldwide¹
- Global MS market sales projected to grow to **USD 41 billion** by 2033 (vs 28.2 billion in 2022).

LUCID-21-302: A POTENTIAL FIRST-IN-CLASS APPROACH TO TREATING DEMYELINATING DISEASES

- **New Chemical Entity** discovered by Dr. Kotra and team at University Health Network
- Mouse models of MS showed **accelerated** functional recovery, **preserved** myelin, and **reduced** axonal degeneration
- First therapy with the potential to **reduce** demyelination and **preserve** neuronal health
- Over 14 years of preclinical R&D showed **promising efficacy**
- **No suppression** of immune system and **no immunomodulation**
- Phase 1 Single-Ascending Dose (SAD) study evaluating the safety and tolerability of Lucid-21-302 in four cohorts has been completed, with **no serious drug-related effects**
- **Potentially Expedited pathway** to market, with Phase 2 clinical trial on the horizon

KOL's predict that neuroprotective therapies are going to be the top priority for new treatments in the future of MS¹

SUMMARY

Led by a **world-class** R&D team and seasoned commercial experts

1,856,900 common shares
USD **13.5 million** cash
Greater than \$7.00 per share

7% royalty on gross revenue of unbuzzd™, with no burden of marketing and operations costs

25% equity stake in Celly Nu, a privately held Canadian company formed in 2023 focused exclusively on unbuzzd™

100% rights to REKVR™, any and all medical and pharmaceutical applications of alcohol misuse treatment

Potential **multi-billion asset** in demyelinating diseases, with an initial indication in multiple sclerosis (MS), and an expedited path to market

100% exclusive worldwide patent rights to New Chemical Entity (NCE) for treatment of multiple sclerosis and other demyelinating disease

FORWARD-LOOKING STATEMENTS

- This Presentation, together with any supplements and any other information that may be furnished to prospective investors by the Company, contains “forward looking information” and “forward looking statements” (forward looking information within the meaning of applicable securities laws). Forward looking information may relate to our future financial outlook and anticipated events or results and may include information regarding our financial position, business strategy, growth strategies, budgets, operations, financial results, taxes, dividend policy, capital structure, plans and objectives, and other statements that are not historical facts. In some cases, forward looking information can be identified by the use of forward looking terminology such as “plans,” “targets,” “does not expect,” “is expected,” “an opportunity exists,” “budget,” “scheduled,” “estimates,” “outlook,” “forecasts,” “projection,” “prospects,” “intends,” “anticipates,” “does not anticipate,” “believes,” “may,” and other similar words or variations of such words. Statements containing forward looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events or circumstances.
- The forward looking information included in this Presentation includes, among other things, statements relating to the design, timing and cost of the Company’s drug candidates and clinical trials; key milestones relating to clinical and regulatory developments; potential market demand for the Company’s drug candidates; near term capital requirements; the anticipated patent and trademark exclusivity periods for the Company’s drug candidates; and the potential role of the Company’s drug candidates in the treatment of Multiple Sclerosis and other inflammatory and degenerative neurological disorders and other orphan diseases. The forward looking information in this Presentation is based on our opinions, estimates and assumptions in light of our experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we currently believe are appropriate and reasonable in the circumstances.
- Despite a careful process to prepare and review the forward looking information, there can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct. The forward looking information in this Presentation is based on a number of assumptions that include, but are not limited to, the following: the Company’s ability to generate sufficient cash flow from operations and obtain financing, if needed, on acceptable terms or at all; the general economic, financial market, regulatory and political conditions in which the Company operates; the interest of potential purchasers in the Company’s drug candidates; anticipated and unanticipated costs; the government regulation of the Company’s activities and drug candidates; the timely receipt of any required regulatory approvals and authorizations and the continuation of previously received regulatory approvals and authorizations; the Company’s ability to obtain qualified staff, equipment and services in a timely and cost efficient manner; the Company’s ability to conduct operations in a safe, efficient and effective manner; and the Company’s expansion plans and timeframe for completion of such plans.